Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Home Page: www.biogen.com
BIIB Technical Analysis
225 Binney Street
Cambridge,
MA
02142
United States
Phone:
617 679 2000
Officers
| Name | Title |
|---|---|
| Mr. Michael R. McDonnell CPA | Exec. VP & CFO |
| Ms. Susan H. Alexander Esq. | Exec. VP, Chief Legal Officer & Sec. |
| Mr. Christopher A. Viehbacher | Pres, CEO & Director |
| Ms. Robin C. Kramer | Sr. VP & Chief Accounting Officer |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology |
| Mr. Michael Hencke | Head of Investor Relations |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corp. Affairs |
| Dr. Ginger Gregory | Exec. VP & Chief HR Officer |
| Dr. Anabella Villalobos Ph.D. | Head of Biotherapeutics & Medicinal Sciences |
| Dr. Sanjay Jariwala | Sr. VP of Worldwide Medical |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 18.4502 |
|---|---|
| Trailing PE: | 14.2121 |
| Price-to-Book MRQ: | 3.2581 |
| Price-to-Sales TTM: | 3.9385 |
| IPO Date: | 1991-09-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 9610 |